Literature DB >> 18479789

Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles.

L Gudmundsdotter1, D Bernasconi, B Hejdeman, E Sandstrom, A Alaeus, K Lidman, B Ensoli, B Wahren, S Buttò.   

Abstract

Individuals infected with different subtypes of HIV-1 (A, B, C, D, CRF01_AE and CRF02_AG) were analyzed for their antigen-specific immune response with respect to their HLA genetics. The p24 Gag protein was selected for analysis, since previous studies of the same cohort of patients had shown that almost 80% of these individuals responded to Gag peptides of subtypes A, B and/or C. A large number of Gag antigen-specific responses were recorded. Both previously recognized as well as new epitopes were identified, assumed to bind HLA classes I and/or II. Fifteen individuals showed class I cellular responses to T cell epitopes irrespective of the infecting virus subtype. For five individuals infected with subtypes A, B, D and CRF02_AG, new T cell epitopes are described. Responses related to the patient's class I alleles are frequent, and several new putative class II responses were found.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479789     DOI: 10.1016/j.vaccine.2008.03.094

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Multiple T-cell epitopes overlap positively-selected residues in the p1 spacer protein of HIV-1 gag.

Authors:  Christina A Semeniuk; Lyle McKinnon; Harold O Peters; Michael Gubbins; Xiaojuan Mao; Terry B Ball; Ma Luo; Francis A Plummer
Journal:  AIDS       Date:  2009-04-27       Impact factor: 4.177

2.  Unique CRF01_AE Gag CTL epitopes associated with lower HIV-viral load and delayed disease progression in a cohort of HIV-infected Thais.

Authors:  Masahiko Mori; Busarawan Sriwanthana; Nuanjun Wichukchinda; Chetsada Boonthimat; Naho Tsuchiya; Toshiyuki Miura; Panita Pathipvanich; Koya Ariyoshi; Pathom Sawanpanyalert
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

3.  Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials.

Authors:  Lycias Zembe; Wendy A Burgers; Heather B Jaspan; Linda-Gail Bekker; Helba Bredell; Gwynneth Stevens; Jill Gilmour; Josephine H Cox; Patricia Fast; Peter Hayes; Eftyhia Vardas; Carolyn Williamson; Clive M Gray
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

4.  The influence of HLA on HIV-associated neurocognitive impairment in Anhui, China.

Authors:  Rachel D Schrier; Saurabh Gupta; Patricia Riggs; Lucette A Cysique; Scott Letendre; Hua Jin; Stephen A Spector; Kumud K Singh; Tanya Wolfson; Zunyou Wu; Kun Xue Hong; Xin Yu; Chuan Shi; Robert K Heaton
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

5.  Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.

Authors:  Nicola Ternette; Peter D Block; Álvaro Sánchez-Bernabéu; Nicola Borthwick; Elisa Pappalardo; Sultan Abdul-Jawad; Beatrice Ondondo; Philip D Charles; Lucy Dorrell; Benedikt M Kessler; Tomáš Hanke
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

6.  The effect of HLA polymorphisms on the recognition of Gag epitopes in HIV-1 CRF01_AE infection.

Authors:  Busarawan Sriwanthana; Masahiko Mori; Mari Tanaka; Sei Nishimura; Toshiyuki Miura; Panita Pathipvanich; Pathom Sawanpanyalert; Koya Ariyoshi
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

7.  The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.

Authors:  Sarah Kutscher; Claudia J Dembek; Simone Allgayer; Silvia Heltai; Birgit Stadlbauer; Priscilla Biswas; Silvia Nozza; Giuseppe Tambussi; Johannes R Bogner; Hans J Stellbrink; Frank D Goebel; Paolo Lusso; Marco Tinelli; Guido Poli; Volker Erfle; Heike Pohla; Mauro Malnati; Antonio Cosma
Journal:  AIDS Res Ther       Date:  2008-10-06       Impact factor: 2.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.